The National Development and Reform Commission is pestering and probing 60 foreign drug makers regarding the prices at which they sell their wares in China. Scrutiny of the foreign drug sector in China made headlines in June when ...
Tags: Harsh Medicine, Pharma Firms
British drug-maker GlaxoSmithKline (GSK) has reached settlement with the attorneys general of eight US states over misleading marketing of the diabetes treatment drug, Avandia, and even agreed to pay $229m to settle the lawsuits. Without ...
Tags: Avandia Lawsuits, Medicine
GlaxoSmithKline (GSK) has reported a profit attributable to shareholders of £1.04bn, or 21.2 pence per diluted share, for the second quarter (Q2) of 2013 compared to £1.24bn, or 24.7 pence in 2012. Cost of sales for the second ...
Tags: Glaxosmithkline, Net Profit
GlaxoSmithKline (GSK) has announced Health Canada approval of a BRAF-inhibitor, Tafinlar, and a first in class MEK-inhibitor, Mekinist, for melanoma patients with BRAF V600 mutation. Both, Tafinlar (dabrafenib mesylate) and Mekinist ...
Tags: Melanoma Drugs, Medicine
UK-based GlaxoSmithKline (GSK) has postponed plans to increase its stake from 46.4% to 75% in GlaxoSmithKline Consumer Nigeria (GSK Nigeria), proposed under a scheme of arrangement. The minority shareholders considered the deal ...
UK health and social care guidance body NICE has again rejected GlaxoSmithKline's (GSK) belimumab (Benlysta) as an add-on therapy in adults with active, autoantibody-positive systemic lupus erythematosus (SLE). Commenting on the second ...
GlaxoSmithKline (GSK) is mulling to establish a joint venture (JV) with a Chinese company as part of its vaccine strategy of teaming up with local partners. The plans come at a time when the company is facing corruption and tax laws ...
Tags: Vaccine Research, GSK
Mergers and acquisitions in the UK food and drink industry hit a 10-year low at just 73 deals in the first half of this year, revealed figures from information services company Experian. Could AG Barr's acquisition of GSK's Lucozade and ...
Tags: Agriculture, Food
GlaxoSmithKline (GSK) and Theravance have withdrawn license application for the use of inhaled drug fluticasone furoate (FF) and vilanterol (VI), with proposed brand name of Relvar Ellipta, as treatment for chronic obstructive pulmonary ...
Tags: Japan, GSK, Relvar License
Shanghai (EASTPO) International Machine Tool Fair is an annual fair. It has been successfully held for 14 sessions since 1999. EASTPO 2012 covered an area of 84,000㎡and 1,139 exhibitors from more than 20 countries and regions as ...
Global pharma companies Sanofi, Novartis and GSK are competing to acquire the domestic formulations business of debt-burdening Elder Pharmaceuticals. People familiar with the matter were quoted by media sources as saying that Sanofi and ...
Tags: Domestic Formulations, Medicine
Aqua Pharmaceuticals has added low-potency foam corticosteroid to its dermatology portfolio with the acquisition of US rights and re-launch of Verdeso (desonide) Foam, 0.05% from Stiefel, a GSK company. Indicated for the topical treatment ...
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's Tafinlar (dabrafenib) and Mekinist (trametinib) as single-agent therapies for unresectable or metastatic melanoma with BRAF V600E mutation. Tafinlar is not indicated ...
GlaxoSmithKline (GSK) has acquired a Switzerland-based vaccines company, Okairos, for €250m in cash to boost its existing vaccine platform technology expertise and to continue developing the next generation of vaccines. Under the ...
Tags: Glaxosmithkline, Vaccines Business
The redundancies will be at the company’s Boronia site, which employs 363 people. GSK said that it is estimated that 120 jobs will be lost through the transformation. However, it also said that any redundancy will not come into ...